Charles Schwab Investment Management Inc. Cuts Holdings in Twist Bioscience Corporation $TWST

Charles Schwab Investment Management Inc. reduced its position in Twist Bioscience Corporation (NASDAQ:TWST) by 5.6% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 512,415 shares of the company’s stock after selling 30,417 shares during the period. Charles Schwab Investment Management Inc. owned 0.86% of Twist Bioscience worth $20,117,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Versant Capital Management Inc increased its stake in Twist Bioscience by 547.2% in the 1st quarter. Versant Capital Management Inc now owns 686 shares of the company’s stock worth $27,000 after acquiring an additional 580 shares during the last quarter. GAMMA Investing LLC grew its holdings in shares of Twist Bioscience by 68.1% in the first quarter. GAMMA Investing LLC now owns 748 shares of the company’s stock valued at $29,000 after purchasing an additional 303 shares in the last quarter. Banque Transatlantique SA bought a new stake in Twist Bioscience in the fourth quarter worth $43,000. GF Fund Management CO. LTD. bought a new stake in Twist Bioscience in the fourth quarter worth $58,000. Finally, Bayforest Capital Ltd raised its stake in Twist Bioscience by 49.3% during the first quarter. Bayforest Capital Ltd now owns 4,860 shares of the company’s stock valued at $191,000 after purchasing an additional 1,604 shares in the last quarter.

Twist Bioscience Stock Performance

Shares of NASDAQ TWST opened at $26.47 on Friday. The company has a 50 day simple moving average of $33.64 and a two-hundred day simple moving average of $36.57. The stock has a market cap of $1.60 billion, a price-to-earnings ratio of -18.26 and a beta of 2.36. The company has a current ratio of 3.90, a quick ratio of 3.60 and a debt-to-equity ratio of 0.03. Twist Bioscience Corporation has a 12 month low of $24.28 and a 12 month high of $55.33.

Twist Bioscience (NASDAQ:TWST) last posted its earnings results on Monday, August 4th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.54) by $0.07. The firm had revenue of $96.06 million during the quarter, compared to analysts’ expectations of $95.52 million. Twist Bioscience had a negative net margin of 23.51% and a negative return on equity of 29.03%. Twist Bioscience has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. As a group, analysts predict that Twist Bioscience Corporation will post -2.12 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on TWST shares. Evercore ISI set a $46.00 price objective on shares of Twist Bioscience in a research note on Monday, August 4th. Cowen reaffirmed a “buy” rating on shares of Twist Bioscience in a report on Monday, August 4th. JPMorgan Chase & Co. reduced their price objective on Twist Bioscience from $40.00 to $33.00 and set an “underweight” rating on the stock in a research note on Tuesday, May 6th. Robert W. Baird reduced their target price on shares of Twist Bioscience from $54.00 to $44.00 and set an “outperform” rating on the stock in a research note on Tuesday, May 6th. Finally, Guggenheim reissued a “buy” rating and set a $50.00 price target on shares of Twist Bioscience in a research note on Tuesday, May 6th. Nine investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $49.40.

Insider Buying and Selling

In related news, CEO Emily M. Leproust sold 1,678 shares of the business’s stock in a transaction that occurred on Friday, June 20th. The stock was sold at an average price of $35.76, for a total transaction of $60,005.28. Following the completion of the sale, the chief executive officer directly owned 645,782 shares in the company, valued at approximately $23,093,164.32. The trade was a 0.26% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Adam Laponis sold 2,449 shares of the stock in a transaction on Wednesday, July 9th. The shares were sold at an average price of $38.15, for a total value of $93,429.35. Following the completion of the transaction, the chief financial officer directly owned 103,569 shares of the company’s stock, valued at approximately $3,951,157.35. This represents a 2.31% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 5,250 shares of company stock worth $193,852 over the last ninety days. Corporate insiders own 3.01% of the company’s stock.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.